Increase Hydrochlorothiazide
In this 66-year-old woman with blood pressure readings of 131/81 to 145/92 on nebivolol 5 mg and hydrochlorothiazide 12.5 mg, you should increase the hydrochlorothiazide to 25 mg rather than increasing the nebivolol. This approach follows the most recent guideline-recommended treatment algorithm and optimizes blood pressure control while minimizing side effects.
Rationale Based on Current Guidelines
The 2025 ACC/AHA hypertension guidelines 1 and 2020 ISH guidelines 2 establish clear treatment pathways for uncontrolled hypertension on dual therapy. When a patient remains above target BP on a beta-blocker plus thiazide diuretic combination, the preferred strategy is to optimize the diuretic dose before escalating other agents.
Key considerations for this specific case:
- Current BP status: Her readings (131/81 to 145/92) indicate Stage 1 hypertension that requires intensification
- Target BP: Should be <130/80 mm Hg per current guidelines 1
- Current regimen: Both medications are at submaximal doses
Why Increase Hydrochlorothiazide First
Dosing Evidence
The hydrochlorothiazide is currently at 12.5 mg, which is half the standard therapeutic dose. According to the 2017 ACC/AHA guidelines 3, 4, hydrochlorothiazide dosing ranges from 12.5-50 mg daily, with 25 mg being the typical effective dose for blood pressure control. Increasing to 25 mg represents standard dose optimization rather than adding complexity.
Multiple factorial design studies 5, 6 demonstrate that hydrochlorothiazide 25 mg combined with nebivolol 5 mg produces superior blood pressure reduction compared to either agent alone at these doses, with sustained 24-hour control and blood pressure loads reduced to 11.5%.
Why Not Increase Nebivolol
Nebivolol 5 mg is already at the standard starting therapeutic dose. While it can be increased to 10-40 mg daily 3, 4, the dose-response curve for beta-blockers tends to plateau, with higher doses primarily increasing side effects (bradycardia, fatigue, sexual dysfunction) rather than providing proportional BP benefits 7.
Beta-blockers are not first-line agents for hypertension unless there are compelling indications (heart failure, post-MI, coronary disease) 3, 4, 1. The guidelines consistently recommend thiazide diuretics, ACE inhibitors, ARBs, or calcium channel blockers as preferred initial therapy, with beta-blockers reserved for specific indications.
Clinical Algorithm
Step 1: Increase hydrochlorothiazide from 12.5 mg to 25 mg daily
Step 2: Reassess BP in 2-4 weeks 8, 2
Step 3: If BP remains >130/80 mm Hg after optimizing HCTZ:
- Consider adding a third agent (ACE inhibitor, ARB, or calcium channel blocker) rather than increasing nebivolol 2, 1
- The 2020 ISH guidelines 2 specifically recommend adding a different drug class at this stage
Step 4: Only increase nebivolol if:
- She has a compelling indication for higher-dose beta-blockade (heart failure, post-MI, angina)
- She cannot tolerate additional HCTZ or a third agent
- Target dose would be 10 mg daily 9, 10
Important Monitoring Considerations
When increasing hydrochlorothiazide to 25 mg:
- Check electrolytes (potassium, sodium) and renal function in 1-2 weeks 3
- Monitor for hypokalemia: More common at 25 mg dose, though the concurrent nebivolol may partially offset this
- Assess glucose: Thiazides can worsen glucose metabolism, though studies show nebivolol may have favorable metabolic effects that counterbalance this 11
- Watch for orthostatic symptoms: Particularly in this 66-year-old patient 12
Common Pitfalls to Avoid
Don't reflexively increase the beta-blocker just because it's listed first or has a lower dose number. The evidence strongly supports optimizing the diuretic component first in this combination.
Don't add a third agent before optimizing existing medications. The 12.5 mg HCTZ dose is subtherapeutic for most patients, and increasing it is the logical next step 5, 6.
Don't ignore the possibility of non-adherence. Before any dose adjustment, confirm the patient is taking medications as prescribed 13, 14. Nebivolol actually shows better adherence rates than HCTZ in real-world studies 14, so if adherence is an issue, the problem is more likely with the diuretic.